Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
91%
Chemotherapy
88%
Liver Cell Carcinoma
85%
Malignant Neoplasm
66%
Metastatic Colorectal Cancer
52%
Phase I Trials
45%
Colorectal Cancer
42%
Temsirolimus
42%
Solid Malignant Neoplasm
42%
Progression Free Survival
41%
Disease
38%
Fluorouracil
38%
Bevacizumab
30%
Microsphere
29%
Liver Metastasis
29%
Cisplatin
28%
Clinical Trial
28%
Immunotherapy
24%
Stomach Cancer
20%
Pancreas Cancer
20%
Neoplasm
19%
Sorafenib
19%
Survival Rate
18%
Yttrium 90
18%
Biological Product
18%
Adverse Event
17%
Phase II Trials
16%
Randomized Clinical Trial
16%
Liver Cancer
16%
Cyclin Dependent Kinase
14%
Protein Kinase C Inhibitor
14%
Biological Marker
14%
Chemotherapy Regimens
14%
3 Aminopicolinaldehyde Thiosemicarbazone
14%
Epidermal Growth Factor Receptor Antibody
14%
Pancreas Adenocarcinoma
14%
Doxorubicin
14%
Pexastimogene Devacirepvec
14%
Pancreatitis
14%
Filgrastim
14%
7 Hydroxystaurosporine
14%
Pancreas Islet Cell Tumor
14%
Hydroxycarbamide
14%
Paclitaxel
14%
Monoclonal Antibody
14%
Interferon
14%
Bryostatin 1
14%
Epithelial Cell Adhesion Molecule
14%
Lenalidomide
14%
Fibroblast Growth Factor 19
14%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Overall Survival
90%
Malignant Neoplasm
51%
Metastatic Colorectal Cancer
32%
Radiation Therapy
31%
Disease
30%
Selective Internal Radiation Therapy
28%
Colorectal Cancer
28%
Progression Free Survival
21%
Pancreas Adenocarcinoma
21%
Surgery
20%
Immunotherapy
17%
Hazard Ratio
17%
Model for End-Stage Liver Disease
16%
Survival Rate
15%
Liver Metastasis
15%
Microsphere
15%
Meta-Analysis
15%
Liver Cancer
14%
Prognostic Factor
14%
FOLFOX
14%
Ablation Therapy
14%
Underserved Population
14%
Phase I Trials
14%
Patient Population
14%
Biological Marker
14%
Stomach Cancer
14%
Neutrophil
14%
Oncology
14%
Socioeconomic Status
14%
Pexastimogene Devacirepvec
14%
Survival Analysis
14%
Chemotherapy
14%
Lymphocyte
14%
Pancreas Cancer
14%
Gemcitabine
14%
Chemoradiotherapy
14%
Pregnane X Receptor
14%
Fibroblast Growth Factor 19
14%
Targeted Therapy
14%
Induction Chemotherapy
14%
Transcatheter Arterial Chemoembolization
14%
Lenalidomide
14%
Therapeutic Modality
14%
Primary Tumor
14%
Proportional Hazards Model
11%
Immune Checkpoint Inhibitor
10%
Sorafenib
7%
Radioembolization
7%
Catheter Ablation
6%
Keyphrases
Metastatic Colorectal Cancer (mCRC)
31%
Phase I Trial
28%
Hepatocellular Carcinoma
28%
Patients with Colorectal Cancer
28%
Hepatocellular Cancer
28%
Clinical Outcomes
23%
Multivariable
17%
MELD-Na
17%
Overall Survival
14%
Phase 1 Trial
14%
Urban Population
14%
Neutrophillymphocyte Ratio
14%
Underserved Populations
14%
Protein Kinase C Inhibitor
14%
Cyclin-dependent Kinase
14%
Antineoplastic Agents
14%
Induction Kinetics
14%
Survival Outcomes
14%
Targeted Therapy
14%
Immunotherapy Efficacy
14%
Triapine
14%
Racially Diverse
14%
PIK3CA Gene
14%
Anti-epidermal Growth Factor Receptor Antibody
14%
Advanced Hepatocellular Carcinoma
14%
Outcome Model
14%
Prognostic Model
14%
7-hydroxystaurosporine
14%
HIV Patients
14%
United States
14%
Bryostatin
14%
Drug-eluting Beads
14%
Cisplatin
14%
Clinical Presentation
14%
Fibroblast Growth Factor 19 (FGF19)
14%
Tumor Aggressiveness
14%
Advanced Stage
14%
Gastroesophageal Junction Carcinoma
14%
Oblimersen
14%
Solid Cancer
14%
Paclitaxel Chemotherapy
14%
Biological Agents
14%
Temsirolimus
14%
ERCC1
14%
Oxaliplatin
14%
Selective Internal Radiation Therapy
14%
Ethnic Minorities
14%
Primary Tumor Sidedness
14%
Extrapancreatic Neuroendocrine Tumors
14%
Diverse Populations
14%